2026-11-19 07:26:32
Selinexor is taken whole with water on fixed weekly days; high-fat meals don’t matter clinically. Myeloma uses 80mg days 1/3 or 100mg weekly, with nausea and hydration managed proactively.
2026-11-17 03:18:41
Avatrombopag and eltrombopag are oral thrombopoietin receptor agonists used in immune thrombocytopenia. They differ in onset pattern, food restrictions, chronic liver disease preoperative labeling, liver monitoring and thrombosis management. All choices must follow prescribing information and physician assessment.
2026-11-17 03:15:05
Differentiation syndrome is a potentially life‑threatening adverse reaction of gilteritinib in acute myeloid leukemia, presenting with fever, dyspnea, effusions, rapid weight gain and hypotension. This article outlines symptoms, timing, management principles and monitoring strategies; all treatment decisions must follow the prescribing information and physician assessment.
2026-11-12 02:49:55
Covers non-CNY pricing logic for branded and generic momelotinib, 200mg once-daily use conversion, anemia and splenomegaly monitoring, and compliant cross-border procurement principles.
2026-11-09 03:21:10
This article reviews clinical data on spleen volume reduction, symptom timing, anemia and transfusion outcomes with momelotinib in myelofibrosis, along with structured follow-up recommendations.
2026-11-09 03:16:39
For mantle cell lymphoma treatment, this article reviews pirtobrutinib’s mechanism, comparative safety data, bleeding and arrhythmia monitoring, anticoagulation use and peri-procedural management.
2026-11-09 01:38:32
This article outlines the standard 28‑day dosing regimen of ixazomib (Ninlaro), timing selection, combination with dexamethasone, handling of missed doses and cycle transition for patients with multiple myeloma.
2026-11-06 05:57:17
A concise overview of the PACE phase II results for ponatinib in patients with prior TKI failure or the T315I mutation, covering response by disease stage, five-year follow-up, and key safety signals.
2026-11-03 03:08:25
Anagrelide is not absolutely forbidden for every high-risk patient. This guide separates clear contraindications from case-by-case precautions across organ function, cardiovascular status, and special populations.
2026-11-02 04:24:52
The FDA label for revumenib lists no formal contraindications, but that does not mean it is appropriate for every patient with leukemia. QTc prolongation, embryo-fetal risk, lactation, CYP3A4-mediated drug interactions, and serious adverse reactions such as differentiation syndrome all require careful assessment before and during therapy.
2026-11-02 04:21:57
Pacritinib is an oral kinase inhibitor targeting JAK2 and IRAK1 signaling, developed for patients with myelofibrosis (MF) who have splenomegaly and debilitating systemic symptoms. Data from the phase III PERSIST-1 and PERSIST-2 trials show meaningful spleen volume reduction and symptom improvement, including in patients with severe thrombocytopenia—a population with historically limited treatment options.
2026-10-30 01:51:07
Pomalidomide is a 3rd-generation IMiD for relapsed/refractory MM; thalidomide is a 1st-gen agent with higher neuropathy risk. Both carry teratogenic and thrombotic risks.